Branches
National Cancer Centre Singapore
Mon—Fri: 8:30 AM — 5:30 PM
Sat: 8:30 AM — 12:30 PM
Closed on Sunday and Public Holidays
Ongoing trials at National Cancer Centre Singapore
72 trials shown
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
This is a phase II study testing the combination of pembrolizumab with lenvatinib, a multi-kinase inhibitor that has activity against vascular endothelial growth factor receptors 1
- Study number:
- NCT05286437
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Hormonal therapy
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
This Phase 1/ 2 study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
- Study number:
- NCT05417932
- Cohorts:
- 1
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy
Novartis
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Study number:
- NCT05358249
- Cohorts:
- 3
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes
- Study number:
- NCT05537740
- Cohorts:
- 1
- Study phase:
- 1
- Overall status:
- Not yet recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors
This is a single group, treatment, Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety and efficacy of SAR444200 as a monotherapy or in combinatio
- Study number:
- NCT05450562
- Cohorts:
- 2
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Targeted therapy
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab pl
- Study number:
- NCT05377034
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Not yet recruiting
- Study type:
- Local/Regional therapies, Immunotherapy, Targeted therapy
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3
- Study number:
- NCT05446870
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Chemotherapy
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally re
- Study number:
- NCT05374512
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Chemotherapy
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers li
- Study number:
- NCT05338970
- Cohorts:
- 2
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-98621
- Study number:
- NCT05328908
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy